Today, I have another controversial prediction. One which I will take no pleasure in seeing come true. See, even with President Trump returning as the leader of our free country, I believe Elon Musk is in mortal danger.

I share with you in this special investigative documentary.

Thane Wettig Biography and Net Worth

Insider of FibroGen

Thane Wettig serves as Chief Commercial Officer of the Company. Mr. Wettig most recently served as Chief Commercial Officer and Metabolic Franchise Head at Intarcia Therapeutics. Prior to joining Intarcia in 2018, Thane spent more than 27 years at Lilly in roles of increasing responsibility, where he served as Vice President of Global Marketing, Strategy and Alliance Management for Lilly Diabetes, leading the development and launch of multiple blockbuster diabetes medicines during a period of unprecedented growth of Lilly's diabetes business. Thane also played an integral role in the design and management of Lilly's highly successful diabetes alliance.

What is Thane Wettig's net worth?: The estimated net worth of Thane Wettig is at least $188,071.20 as of March 7th, 2024. Mr. Wettig owns 470,178 shares of FibroGen stock worth more than $188,071 as of December 21st. This net worth estimate does not reflect any other investments that Mr. Wettig may own. Additionally, Mr. Wettig receives a salary of $941,790.00 as Insider at FibroGen. Learn More about Thane Wettig's net worth.
How old is Thane Wettig?: Mr. Wettig is currently 59 years old. There are 3 older executives and no younger executives at FibroGen. Learn More on Thane Wettig's age.
What is Thane Wettig's salary?: As the Insider of FibroGen, Inc., Mr. Wettig earns $941,790.00 per year. Learn More on Thane Wettig's salary.
How do I contact Thane Wettig?: The corporate mailing address for Mr. Wettig and other FibroGen executives is 409 ILLINOIS STREET, SAN FRANCISCO CA, 94158. FibroGen can also be reached via phone at (415) 978-1200 and via email at [email protected]. Learn More on Thane Wettig's contact information.
Has Thane Wettig been buying or selling shares of FibroGen?: Thane Wettig has not been actively trading shares of FibroGen over the course of the past ninety days. Most recently, on Thursday, March 7th, Thane Wettig bought 50,000 shares of FibroGen stock. The stock was acquired at an average cost of $1.91 per share, with a total value of $95,500.00. Following the completion of the transaction, the chief executive officer now directly owns 470,178 shares of the company's stock, valued at $898,039.98. Learn More on Thane Wettig's trading history.
Who are FibroGen's active insiders?: FibroGen's insider roster includes Pat Cotroneo (CFO), Thomas Kearns, Jr. (Director), and Thane Wettig (Insider). Learn More on FibroGen's active insiders.
Are insiders buying or selling shares of FibroGen?: In the last year, FibroGen insiders bought shares 2 times. They purchased a total of 72,123 shares worth more than $121,383.91. The most recent insider tranaction occured on June, 12th when insider Deyaa Adib bought 22,123 shares worth more than $25,883.91. Insiders at FibroGen own 2.0% of the company. Learn More about insider trades at FibroGen.
Information on this page was last updated on 6/12/2024.

Thane Wettig Insider Trading History at FibroGen

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/7/2024	Buy	50,000	$1.91	$95,500.00	470,178
6/23/2023	Sell	791	$16.53	$13,075.23	108,261
6/7/2023	Sell	1,758	$17.04	$29,956.32	111,395
3/23/2023	Sell	905	$18.71	$16,932.55	110,653
12/23/2022	Sell	734	$15.80	$11,597.20	89,163
12/8/2022	Sell	382	$15.79	$6,031.78	89,897
8/26/2021	Buy	3,100	$11.53	$35,743.00

Thane Wettig Buying and Selling Activity at FibroGen

FibroGen Company Overview

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.

Today's Range

Now: $0.40

$0.35

$0.43

50 Day Range

MA: $0.35

$0.30

$0.42

2 Week Range

Now: $0.40

$0.18

$2.93

Volume

3,363,930 shs

Average Volume

2,111,790 shs

Market Capitalization

$40.31 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.82

First JFK… next Elon?

From Porter & Company | Ad

I share with you in this special investigative documentary.

Thane Wettig Biography and Net Worth

What is Thane Wettig's net worth?

How old is Thane Wettig?

What is Thane Wettig's salary?

How do I contact Thane Wettig?

Has Thane Wettig been buying or selling shares of FibroGen?

Who are FibroGen's active insiders?

Are insiders buying or selling shares of FibroGen?